Download Mobile App

Video Library

Partner Sites

MedImaging

AI Tool Improves Medical Imaging Process by 90%

Ultrasound Probe Images Entire Organ in 4D

AI Generates Future Knee X-Rays to Predict Osteoarthritis Progression Risk

New Imaging Solution Improves Survival for Patients with Recurring Prostate Cancer

Disposable Ultrasound Patch Performs Better Than Existing Devices

Novartis To Begin Phase III Clinical Trial of Autoimmune Disease Drug in COVID-19 Patients with Pneumonia

By HospiMedica International staff writers
Posted on 02 May 2020

Novartis (Basel, Switzerland) will initiate a Phase III clinical trial to examine the efficacy of utilizing canakinumab, an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia.

The study builds on early evidence from lab tests of COVID-19 patients who showed elevated IL-1β levels, among other cytokines. More...

For the CAN-COVID trial, Novartis aims to rapidly enroll 450 patients at multiple medical centers across France, Germany, Italy, Spain, the UK and US and randomize them to receive either canakinumab or placebo on top of standard of care (SoC).

The primary objective of the study is to demonstrate the benefit of canakinumab in combination with SoC in increasing the chance of survival without the need for invasive mechanical ventilation among patients with COVID-19 pneumonia. Top-line results are anticipated late summer 2020.

Related Links:
Novartis

Visit expo >

Gold Member

POC Blood Gas Analyzer

Stat Profile Prime Plus

Antipsychotic TDM Assays
Saladax Antipsychotic Assays

Radiation Safety Barrier

RayShield Intensi-Barrier

Ultrasound Needle Guidance System

SonoSite L25

Read the full article by registering today, it's FREE!

Free digital version edition of HospiMedica International sent by email on regular basis
Free print version of HospiMedica International magazine (available only outside USA and Canada).
Free and unlimited access to back issues of HospiMedica International in digital format
Free HospiMedica International Newsletter sent every week containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!